Fourth Vaccine Candidate Launches Phase 3 Trials

Johnson & Johnson vaccine is a single dose not requiring ultra-cold storage.

Johnson & Johnson started human trials for their COVID-19 vaccine candidate this week. They intend to enroll up to 60,000 people in the trial and claim advantages over other vaccines being tested of not requiring unusually cold refrigeration and its single-dose nature. Should the potential vaccine be proven safe and effective, the first doses are expected to be ready early next year.

Through “Operation Warp Speed,” the president’s administration has enabled private pharmaceutical manufacturers to expedite the formulation and testing of vaccines for the coronavirus. Drug makers AstraZeneca, Pfizer, and Moderna have potential vaccines in Phase 3 trials already and anticipate data on their effectiveness rates by the end of October.

As the Lord Leads, Pray with Us…

  • For the Phase 3 trial subjects to respond favorably to testing. 
  • That the Food and Drug Administration is able to approve a safe vaccine to the American public in a timely fashion.
  • For the president’s administration as they continue to support the pandemic recovery. 

Sources: The Hill, Washington Post


Back to top